News

News about advances made possible through IPIRA's work, such as innovations commercialized, campus partnerships with industry, and companies born out of licensing UC Berkeley intellectual property rights.

All News

January 12, 2026

Tessera Therapeutics Announces FDA Clearance of IND Application for its Lead In Vivo Gene Editing Program TSRA-196 for AATD

link

December 1, 2025

Regeneron makes $150M bet on Tessera's rare disease gene writing prospect

link

October 8, 2025

Tessera Therapeutics Awarded up to $41.3 Million from ARPA-H to Advance In Vivo CAR-T Therapies

link

December 18, 2024

Tessera Therapeutics Receives Investment to Develop Curative In Vivo Genetic Treatment for Sickle Cell Disease

Link

October 27, 2023

Tessera Therapeutics Awarded the Prix Galien USA 2023 for Best Startup

Link